Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Experimental Arm: Cabozantinib + Atezolizumab	432
Overall Study	STARTED	Single-Agent Cabozantinib	188
Overall Study	STARTED	Control Arm: Sorafenib	217
Overall Study	Received At Least 1 Dose of Study Drug	Experimental Arm: Cabozantinib + Atezolizumab	429
Overall Study	Received At Least 1 Dose of Study Drug	Single-Agent Cabozantinib	188
Overall Study	Received At Least 1 Dose of Study Drug	Control Arm: Sorafenib	207
Overall Study	COMPLETED	Experimental Arm: Cabozantinib + Atezolizumab	0
Overall Study	COMPLETED	Single-Agent Cabozantinib	0
Overall Study	COMPLETED	Control Arm: Sorafenib	0
Overall Study	NOT COMPLETED	Experimental Arm: Cabozantinib + Atezolizumab	432
Overall Study	NOT COMPLETED	Single-Agent Cabozantinib	188
Overall Study	NOT COMPLETED	Control Arm: Sorafenib	217

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03755791/flow